<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688346</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00006670</org_study_id>
    <nct_id>NCT04688346</nct_id>
  </id_info>
  <brief_title>Cardiovascular Effects of Racemic Epinephrine Pellets</brief_title>
  <official_title>Cardiovascular Effects of Racemic Epinephrine Pellets Used in Pediatric Restorative Dentistry Under General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study was to determine if topical racemic epinephrine pellets affect&#xD;
      heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP) or mean&#xD;
      arterial pressure (MAP) in children receiving dental care under general anesthesia (GA).&#xD;
      Thirteen patients requiring prefabricated zirconia crowns on both primary maxillary first&#xD;
      molars were recruited into a split-mouth randomized controlled pilot study. Patients received&#xD;
      a continuous infusion of propofol and remifentanil with inhaled nitrous oxide/oxygen. After&#xD;
      patient randomization and tooth preparation, either saline pellets (control) or racemic&#xD;
      epinephrine pellets (treatment) were applied directly to gingival tissue. Vital sign&#xD;
      measurements were recorded for 5 minutes. The procedure was repeated with either control or&#xD;
      treatment on the contralateral side.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dental caries is the most common chronic disease of childhood. 3-6% of US children experience&#xD;
      early childhood caries, a condition that may necessitate restorative dental treatment.&#xD;
      Prefabricated crowns are the treatment of choice for children with rampant caries involving&#xD;
      large or multiple surface lesions or developmental defects. In such situations, crowns&#xD;
      reinforce the tooth and provide increased durability and longevity over intracoronal&#xD;
      restorations such as fillings. They also reduce the chance that the tooth will experience&#xD;
      recurrent decay.&#xD;
&#xD;
      In routine clinical practice, preformed metal crowns, also known as stainless steel crowns&#xD;
      (SSC) are frequently indicated due to their extreme durability, relatively low cost, and&#xD;
      minimal technique sensitivity. Stainless steel crowns (SSC) are no longer the only standard&#xD;
      of care in restoring primary teeth. Although SSCs are highly effective, esthetics can be a&#xD;
      concern for parents. Prefabricated zirconia crowns provide an esthetic solution. Zirconia is&#xD;
      a crystalline dioxide of zirconium that has mechanical properties similar to those of metals&#xD;
      while its color is similar to that of teeth. According to a recent randomized controlled&#xD;
      trial, both SSC and zirconia crowns proved to be an excellent choice for molar teeth full&#xD;
      coverage restorations. However, zirconia crowns performed better from the standpoint of&#xD;
      esthetics, gum tissue response and plaque retention. (Abdulhadi Bashaer S, Abdullah Medhat M,&#xD;
      et al. Clinical evaluation between zirconia crowns and stainless steel crowns in primary&#xD;
      molars teeth. Journal of pediatric dentistry. 2017, Vol 5, issue 1; 21-27.)&#xD;
&#xD;
      Both Stainless steel crown and zirconia crown preparations include removing caries, followed&#xD;
      by reducing the height of the tooth by 1.5 mm, reducing the sides of the tooth to make the&#xD;
      pre-fabricated crown fit on the tooth. The SSC preparation requires subgingival reduction 1-2&#xD;
      mm below the gumline on anterior and posterior surfaces (not medial and lateral). The only&#xD;
      additional preparation step that zirconia crown preparation involves is medial and lateral&#xD;
      reduction of the tooth; therefore, there is little additional time that is needed for&#xD;
      preparation of the crown since the only difference is the depth of the side reduction and&#xD;
      preparing it circumferentially. In addition, the Primary Investigator (PI) is the provider&#xD;
      who will be treating all patients. The PI is an experienced pediatric dentist and has been&#xD;
      providing both types of crowns to patients under general anesthesia every week for many&#xD;
      years.&#xD;
&#xD;
      The average time for a dental procedure under general anesthesia is between 1-3 hours.&#xD;
      Factors that increase time include extent of disease, number of fillings/crowns placed, and&#xD;
      pediatric dentist's experience.&#xD;
&#xD;
      The pediatric dentist that will be doing the surgery on all patients has been practicing for&#xD;
      many years and has prepared thousands of SSC and zirconia crowns. Therefore, it is not&#xD;
      anticipated that it will require additional time to prepare the zirconia crowns versus&#xD;
      stainless steel crowns.&#xD;
&#xD;
      Vital signs (BP and HR) will be monitored for 4 minutes/tooth, 5-8 minutes total (See&#xD;
      attached chart showing the difference). During this time the patient will be continuously&#xD;
      anesthetized and under close observation by the attending anesthesiologist. This constitutes&#xD;
      a minimal risk to a child's health.&#xD;
&#xD;
      According to studies, epinephrine half-life is about two minutes and once the epinephrine&#xD;
      pellet is removed, concentrations will drop by 93.75% over 4 half-lives which is about 8&#xD;
      minutes. Therefore, if there is any effect on blood pressure it will show immediately and&#xD;
      will go back to normal within the time frame that we are recording data. The procedure will&#xD;
      be stopped if the blood pressure is at a harmful range to patient.&#xD;
&#xD;
      All children will have both of their maxillary primary first molars (#B, #I) prepared for&#xD;
      prefabricated Zirconia crowns. Teeth that require pulpotomy or pulpectomy treatment will be&#xD;
      excluded from the study.&#xD;
&#xD;
      In the control group, hemostasis will be achieved by using two pellets soaked with 0.9%&#xD;
      sodium chloride (physiological saline). In the intervention group, hemostasis will be&#xD;
      achieved by using two racemic epinephrine HCl pellets (HemeRX, Racellet #3, Sprig Oral Health&#xD;
      Technologies, Inc. Loomis, CA). Racellet #3 contains an average of 0.55 mg (0.42 to 0.68&#xD;
      mg/pellet) of racemic epinephrine hydrochloride per pellet.&#xD;
&#xD;
      A standard general anesthesia protocol will be used during the study. All monitoring&#xD;
      equipment will be applied at this time for the measurement of vital signs throughout the&#xD;
      anesthesia. Vital signs will include: respiratory rate, oxygen-saturated hemoglobin&#xD;
      percentage, heart rate (HR) in beats per minute (bpm) and cardiac rhythm, which will be&#xD;
      continuously recorded from a 3-lead electrocardiogram (ECG). The systolic blood pressures&#xD;
      (SBP) and diastolic blood pressures (DBP) will be measured in millimeters of mercury (mmHg)&#xD;
      via ankle artery cuff connected to monitors.&#xD;
&#xD;
      Investigators will use a randomization software before the enrollment of the first subject to&#xD;
      randomly determine if the right or the left side of the mouth will be the intervention. Once&#xD;
      consent is obtained, randomization software will be used again to determine whether the&#xD;
      patient will be given control or intervention treatment first. Once patients are under&#xD;
      anesthesia and after other dental treatments are completed, the maxillary first primary&#xD;
      molars (#B, #I) will be prepared for Zirconia crowns. The crowns will be prepared&#xD;
      independently. One tooth will be prepared first, the pre-fabricated crown will be tried on to&#xD;
      make sure the fit is correct. Next either intervention or control pellets will be placed&#xD;
      around the gumline of the tooth and removed after one minute. The vital signs will continue&#xD;
      to be recorded for the next 4 minutes meanwhile he crown is being cemented on the tooth. Once&#xD;
      that is done the operator will move to the other tooth and repeat the same steps.&#xD;
&#xD;
      The process of preparing the tooth for a Zirconia crown requires a circumferential&#xD;
      subgingival preparation. Tissue irritation and bleeding is inherent in this process. Once the&#xD;
      crown is ready to be permanently cemented hemostasis becomes very important. In both the&#xD;
      control and intervention group of teeth, two pellets will be applied directly around the&#xD;
      gingival tissue of the prepared tooth and held for one minute with direct pressure and then&#xD;
      removed based on the manufacturer's recommendation. The time of application will be recorded.&#xD;
      The adequacy of hemostasis will be determined subjectively by the attending dentist and&#xD;
      recorded as &quot;adequate&quot; or &quot;inadequate&quot; at 1, 2, 3, 4, and 5 minutes after placement. Adequate&#xD;
      hemostasis is defined as gingival tissue being dry and hemorrhage-free. Inadequate hemostasis&#xD;
      is defined as inability to keep the gingival tissue dry and without hemorrhage. If hemostasis&#xD;
      is not achieved after four minutes of managing a subject during the study intervention&#xD;
      (saline or epinephrine pellets) to which a tooth has been randomized, we will revert to the&#xD;
      standard of care in order to stop the bleeding. Lidocaine will not be administered as a&#xD;
      primary local anesthetic nor would it be used during our study. Only epinephrine pellets and&#xD;
      saline pellets will be used in the study for achieving hemostasis.&#xD;
&#xD;
      Cardiovascular outcomes of patient's systolic blood pressure (SBP), diastolic blood pressure&#xD;
      (DBP) and heart rate (HR) will be collected by the graduate researcher during the procedure.&#xD;
      The researcher will record the blood pressure/HR before placement of pellets, immediately&#xD;
      after placement and at 1, 2, 3, 4, 5 minutes after placement. The pellets will stay on the&#xD;
      tissue for 1 minute only and then removed. The researcher will also record hemostasis&#xD;
      efficacy as per dental surgeon as either &quot;adequate&quot; or &quot;inadequate&quot; during the procedure.&#xD;
&#xD;
      In addition to the above measurements, cardiac rhythms will be assessed continuously via ECG&#xD;
      and recording any arrhythmias. Mean arterial pressure (MAP), the amount of time in surgery&#xD;
      and anesthesia medications used for each patient will also be recorded. All patients will be&#xD;
      discharged on the same day after adequate recovery observation time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2019</start_date>
  <completion_date type="Actual">November 30, 2019</completion_date>
  <primary_completion_date type="Actual">November 30, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a, single-blinded, placebo-controlled, split-mouth randomized trial. A sample size of 20 pediatric patients will be used for this pilot study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular Outcomes</measure>
    <time_frame>5 minutes</time_frame>
    <description>To determine heart rate change of patients receiving treatment with topical racemic epinephrine compared to those receiving a placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular Outcomes</measure>
    <time_frame>5 minutes</time_frame>
    <description>To determine blood pressure change of patients receiving treatment with topical racemic epinephrine compared to those receiving a placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemostasis Efficacy</measure>
    <time_frame>5 minutes</time_frame>
    <description>To determine time to achieving hemostasis (based upon subjective assessment of surgeon) on patients receiving treatment with topical racemic epinephrine compared to those receiving a placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Epinephrine Causing Adverse Effects in Therapeutic Use</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Pellet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Racemic Epinephrine Pellet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HemeRX epinephrine pellets</intervention_name>
    <description>Racemic Epinephrine Pellet</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Children ages 2-9 years undergoing general anesthesia for comprehensive dental&#xD;
             treatment at the University of Washington Center of Pediatric Dentistry.&#xD;
&#xD;
          2. Healthy patients according to the American Society of Anesthesiologists (ASA)&#xD;
             classification I or II.&#xD;
&#xD;
          3. Patients who have caries lesions requiring prefabricated crowns on primary maxillary&#xD;
             first molars #B and #I.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pediatric patients with any severe systemic illness (ASA Classification III or&#xD;
             greater).&#xD;
&#xD;
          2. Pediatric patients with known cardiac arrhythmia, cardiovascular disease, diabetes and&#xD;
             thyroid disease.&#xD;
&#xD;
          3. Patients who are taking anti-arrhythmic, antihypertensive, or ionotropic medications.&#xD;
&#xD;
          4. Patients who would need pulpotomy or pulpectomy treatment on primary maxillary first&#xD;
             molars #B and I.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Travis M Nelson, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UW Center for Pediatric Dentistry</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <results_first_submitted>March 19, 2021</results_first_submitted>
  <results_first_submitted_qc>May 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2021</results_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Travis Nelson</investigator_full_name>
    <investigator_title>Clinical Associate Professor, School of Dentistry</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 23, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT04688346/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>13 participants were enrolled. Each served as their own control. Left side primary maxillary molar received Saline, right side received Epinephrine pellets.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Saline First, Then Epinephrine</title>
          <description>Saline Pellet&#xD;
HemeRX epinephrine pellets: Racemic Epinephrine Pellet</description>
        </group>
        <group group_id="P2">
          <title>First Epinephrine, Then Saline</title>
          <description>Racemic Epinephrine Pellet&#xD;
HemeRX epinephrine pellets: Racemic Epinephrine Pellet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>First Intervention</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Second Intervention</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Saline First, Then Epinephrine</title>
          <description>Saline Pellet&#xD;
HemeRX epinephrine pellets: Racemic Epinephrine Pellet</description>
        </group>
        <group group_id="B2">
          <title>First Epinephrine, Then Saline</title>
          <description>Racemic Epinephrine Pellet&#xD;
HemeRX epinephrine pellets: Racemic Epinephrine Pellet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="1.5"/>
                    <measurement group_id="B2" value="4.5" spread="1.7"/>
                    <measurement group_id="B3" value="4.7" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cardiovascular Outcomes</title>
        <description>To determine heart rate change of patients receiving treatment with topical racemic epinephrine compared to those receiving a placebo.</description>
        <time_frame>5 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Saline Pellet&#xD;
HemeRX epinephrine pellets: Racemic Epinephrine Pellet</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Racemic Epinephrine Pellet&#xD;
HemeRX epinephrine pellets: Racemic Epinephrine Pellet</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular Outcomes</title>
          <description>To determine heart rate change of patients receiving treatment with topical racemic epinephrine compared to those receiving a placebo.</description>
          <units>Beats Per Minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5" spread="18.2"/>
                    <measurement group_id="O2" value="93.4" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cardiovascular Outcomes</title>
        <description>To determine blood pressure change of patients receiving treatment with topical racemic epinephrine compared to those receiving a placebo.</description>
        <time_frame>5 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Saline Pellet&#xD;
HemeRX epinephrine pellets: Racemic Epinephrine Pellet</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Racemic Epinephrine Pellet&#xD;
HemeRX epinephrine pellets: Racemic Epinephrine Pellet</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular Outcomes</title>
          <description>To determine blood pressure change of patients receiving treatment with topical racemic epinephrine compared to those receiving a placebo.</description>
          <units>mmhg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="5.1"/>
                    <measurement group_id="O2" value="-2.7" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemostasis Efficacy</title>
        <description>To determine time to achieving hemostasis (based upon subjective assessment of surgeon) on patients receiving treatment with topical racemic epinephrine compared to those receiving a placebo.</description>
        <time_frame>5 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Saline Pellet&#xD;
HemeRX epinephrine pellets: Racemic Epinephrine Pellet</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Racemic Epinephrine Pellet&#xD;
HemeRX epinephrine pellets: Racemic Epinephrine Pellet</description>
          </group>
        </group_list>
        <measure>
          <title>Hemostasis Efficacy</title>
          <description>To determine time to achieving hemostasis (based upon subjective assessment of surgeon) on patients receiving treatment with topical racemic epinephrine compared to those receiving a placebo.</description>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="2"/>
                    <measurement group_id="O2" value="2.2" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>t-test</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were assessed for adverse outcomes during the period of their general anesthesia visit (1 day).</time_frame>
      <desc>cardiac and hematological adverse outcomes</desc>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Saline Pellet&#xD;
HemeRX epinephrine pellets: Racemic Epinephrine Pellet</description>
        </group>
        <group group_id="E2">
          <title>Intervention</title>
          <description>Racemic Epinephrine Pellet&#xD;
HemeRX epinephrine pellets: Racemic Epinephrine Pellet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Travis Nelson</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-290-2899</phone>
      <email>tmnelson@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

